These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 12649189)

  • 61. Practical theoretic guidance for the design of tumor-targeting agents.
    Wittrup KD; Thurber GM; Schmidt MM; Rhoden JJ
    Methods Enzymol; 2012; 503():255-68. PubMed ID: 22230572
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Kinetic measurements of molecular interactions by spectrofluorometry.
    Voss EW
    J Mol Recognit; 1993 Jun; 6(2):51-8. PubMed ID: 8305251
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Affinity and avidity in antibody-based tumor targeting.
    Rudnick SI; Adams GP
    Cancer Biother Radiopharm; 2009 Apr; 24(2):155-61. PubMed ID: 19409036
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Direct binding of radioiodinated monoclonal antibody to tumor cells: significance of antibody purity and affinity for drug targeting or tumor imaging.
    Kennel SJ; Foote LJ; Lankford PK; Johnson M; Mitchell T; Braslawsky GR
    Hybridoma; 1983; 2(3):297-310. PubMed ID: 6678798
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mathematical models of prevascular spheroid development and catastrophe-theoretic description of rapid metastatic growth/tumor remission.
    Adam JA
    Invasion Metastasis; 1996; 16(4-5):247-67. PubMed ID: 9311389
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Theoretic criteria for antibody penetration into solid tumors and micrometastases.
    Thurber GM; Zajic SC; Wittrup KD
    J Nucl Med; 2007 Jun; 48(6):995-9. PubMed ID: 17504872
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacokinetics and biodistribution of genetically engineered antibodies.
    Batra SK; Jain M; Wittel UA; Chauhan SC; Colcher D
    Curr Opin Biotechnol; 2002 Dec; 13(6):603-8. PubMed ID: 12482521
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [The dynamics of antigen-antibody complex formation in the presence of iodine-containing diagnostic agents].
    Shabunin IV; Panov VO; Avdienko VV; Shimanovskiĭ NL
    Eksp Klin Farmakol; 2000; 63(2):63-6. PubMed ID: 10834099
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Towards a quantitative model of immunogenicity: counting pathways in sequence space.
    Chang TY
    J Theor Biol; 2000 Sep; 206(2):255-78. PubMed ID: 10966763
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Affinity thin-layer chromatography test of the immunoreactive fraction of radiolabeled antibodies.
    Zamora PO; Sass K; Cardillo AS; Lambert CR; Budd P; Marek MJ; Rhodes BA
    Biotechniques; 1994 Feb; 16(2):306-11. PubMed ID: 8179894
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mathematical and experimental analysis of localization of anti-tumour antibody-enzyme conjugates.
    Jackson TL; Lubkin SR; Siemers NO; Kerr DE; Senter PD; Murray JD
    Br J Cancer; 1999 Aug; 80(11):1747-53. PubMed ID: 10468291
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Finite element model of antibody penetration in a prevascular tumor nodule embedded in normal tissue.
    Banerjee RK; van Osdol WW; Bungay PM; Sung C; Dedrick RL
    J Control Release; 2001 Jul; 74(1-3):193-202. PubMed ID: 11489495
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The macroscopic and microscopic pharmacology of monoclonal antibodies.
    Weinstein JN; van Osdol W
    Int J Immunopharmacol; 1992 Apr; 14(3):457-63. PubMed ID: 1618598
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Relationship between the reaching of equilibrium and the accuracy of the affinity determination for antibody-antigen reaction].
    Bobrovnik SA; Demchenko MA; Komisarenko SV
    Ukr Biokhim Zh (1999); 2010; 82(3):68-74. PubMed ID: 21328880
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Antibody pharmacokinetics and pharmacodynamics.
    Lobo ED; Hansen RJ; Balthasar JP
    J Pharm Sci; 2004 Nov; 93(11):2645-68. PubMed ID: 15389672
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Present status of biological markers in oncology].
    Valladares Y
    Rev Esp Oncol; 1985; 32(1):129-61. PubMed ID: 3843000
    [No Abstract]   [Full Text] [Related]  

  • 77. Anti-cooperativity in diffusion-controlled reactions with pairs of anisotropic domains: a model for the antigen-antibody encounter.
    Piazza F; Rios Pde L; Fanelli D; Bongini L; Skoglund U
    Eur Biophys J; 2005 Oct; 34(7):899-911. PubMed ID: 15803329
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.
    Thurber GM; Schmidt MM; Wittrup KD
    Adv Drug Deliv Rev; 2008 Sep; 60(12):1421-34. PubMed ID: 18541331
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Comparative analysis of models describing interactions between antibodies and liposomal antigens].
    Gendrikson OD; Zherdev AV; Kaplun AP; Dzantiev BB
    Prikl Biokhim Mikrobiol; 2003; 39(1):85-91. PubMed ID: 12625047
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Receptor imaging: competitive or complementary to antibody imaging?
    Goldsmith SJ
    Semin Nucl Med; 1997 Apr; 27(2):85-93. PubMed ID: 9144853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.